Spruce Price To Sales Ratio from 2010 to 2024
| SPRB Stock | USD 0.48 0.01 2.04% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 10.07 | Current Value 8.94 | Quarterly Volatility 0.62817985 |
Check Spruce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spruce Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 4 M, Depreciation And Amortization of 66.5 K or Interest Expense of 299.9 K, as well as many indicators such as Price To Sales Ratio of 8.94, Dividend Yield of 0.0 or PTB Ratio of 1.55. Spruce financial statements analysis is a perfect complement when working with Spruce Biosciences Valuation or Volatility modules.
Spruce | Price To Sales Ratio |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out the analysis of Spruce Biosciences Correlation against competitors. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.